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ABSTRACT Word count: 250 (limit 250) 
Introduction: In pivotal trials of patients with autosomal dominant polycystic kidney disease at 
risk of rapid progression, tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in 
early-to-moderate (TEMPO 3:4 [NCT00428948]) and moderate-to-late stage (REPRISE 
[NCT02160145]) chronic kidney disease (CKD). Discontinuation was less frequent in REPRISE 
(15.0%) than TEMPO 3:4 (23.0%), given that in REPRISE, only subjects who tolerated tolvaptan 
60/30 mg daily initiated the double-blind phase. We evaluated whether the greater treatment effect 
in REPRISE was attributable to different completion rates. 
 
Methods: We conducted post hoc analyses of TEMPO 3:4 and REPRISE completers, defined as 
subjects who took trial drug to the end of the treatment period in TEMPO 3:4 (3 years) or REPRISE 
(1 year). Efficacy (rate of change in eGFR for tolvaptan versus placebo) was analyzed as in each 
trial. Subjects from TEMPO 3:4 and REPRISE were also matched by propensity score for age, 
gender, and baseline eGFR to explore potential additional determinants of treatment effect. 
 
Results: The annualized tolvaptan treatment effect in TEMPO 3:4 completers (difference versus 
placebo of 0.98 mL/min/1.73 m2/year) and REPRISE completers (difference of 1.23) was similar to 
that of the respective total trial populations (TEMPO 3:4: 0.94; REPRISE: 1.27). The treatment effect 
of tolvaptan was also similar between matched subjects.  
 
Conclusion: Greater treatment completion rate did not drive greater treatment effect in REPRISE. 
The more advanced CKD of REPRISE subjects may be more relevant. More rapid decline in kidney 
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Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney 
condition and a leading cause of end-stage kidney disease (ESKD) globally.1–4 Tolvaptan, a 
vasopressin receptor antagonist, is the first drug to be approved for the treatment of ADPKD and 
has been licensed in a number of regions including the United States, Europe, Japan, Korea, and 
Australia.5–7 The drug exerts its therapeutic effects by targeting V2 receptors in renal epithelial 
cells, resulting in downregulation of the intracellular cyclic adenosine monophosphate (cAMP) 
signaling pathway. Cystic growth has been linked to upregulation of the cAMP pathway in ADPKD, 
as reviewed elsewhere.5,8–11 The evidence for tolvaptan effectiveness is based on results from the 3-
year TEMPO 3:4 (NCT00428948) and the 1-year REPRISE (NCT02160145) clinical trials. The trials 
demonstrated that tolvaptan slows estimated glomerular filtration rate (eGFR) decline and total 
kidney volume (TKV) growth compared to placebo in ADPKD subjects at risk of rapid 
progression.12,13  
Inhibition of vasopressin activity also decreases urine concentrating activity and is 
associated with aquaretic adverse events (AAEs; e.g., polyuria, thirst, nocturia, pollakiuria), which 
can negatively impact adherence to treatment.14 In TEMPO 3:4, 23.0% of tolvaptan-treated subjects 
discontinued from the trial early; the most common reason for discontinuation was adverse events 
(15.4% of subjects), and those most frequently leading to discontinuation were AAEs (8.3% of 
subjects).12 The double-blind treatment phase of REPRISE included only subjects who tolerated 
tolvaptan at a split dose of at least 60/30 mg during a preceding single-blind tolvaptan treatment 
phase. Compared to TEMPO 3:4, discontinuations were, therefore, less frequent during the double-
blind phase of REPRISE: 15.0% of subjects in the tolvaptan arm discontinued treatment; 9.5% 
discontinued due to adverse events, and 2.1% discontinued due to AAEs.13  
Both trials were analyzed in accordance with the intention-to-treat (ITT) principle, which 










regard for noncompliance, protocol deviations, or early withdrawal.15,16 Intention-to-treat is an 
established feature of interventional clinical trial design intended to minimize bias in the estimation 
of treatment effect that would arise from the exclusion of subjects nonadherent to study treatment. 
The approach is mandated by many regulatory bodies, even if studies go on to also include 
additional per-protocol or as-treated analyses.17,18 However, it is widely recognized that in 
scenarios where there are high levels of nonadherence to a trial  treatment, ITT analysis may 
substantially underestimate the effect of a therapy.16 
To evaluate the possibility that subjects who completed their respective trials on treatment 
would show a larger effect size than those who terminated treatment early, we conducted a post 
hoc analysis. The primary objective of this analysis was to assess the effects of tolvaptan on eGFR in 
subgroups of TEMPO 3:4 and REPRISE trial subjects who completed the follow-up period on 
treatment. A secondary objective was to explore the potential effects of treatment completion on 
the magnitude of treatment responses observed in TEMPO 3:4 and REPRISE.  
 
METHODS 
TEMPO 3:4 and REPRISE Trial Design and Population 
TEMPO 3:4 and REPRISE trial design and enrollment criteria have been described 
previously.12,13 Both were randomized, double-blind, placebo-controlled trials. In TEMPO 3:4, 
tolvaptan was initiated at a daily split dose of 45/15 mg, which was increased weekly to 60/30 mg 
and then to 90/30 mg, based on subject-reported tolerability. Subjects took the highest tolerable 
dose for the 36-month treatment period.  
In REPRISE, all subjects received tolvaptan during a single-blind, 5-week titration and run-
in phase. Those who tolerated a 60/30 mg or 90/30 mg dose were then randomized to 12 months 
of double-blind tolvaptan or placebo. Tolvaptan was taken at the highest dose tolerated (with a 











Both studies targeted ADPKD populations with a high likelihood of rapid disease 
progression. TEMPO 3:4 enrolled subjects with preserved renal function: 18-50 years old with 
estimated creatinine clearance ≥60 mL/min and TKV ≥750 mL. REPRISE enrolled an older 
population with more advanced disease: ages 18−55 years with eGFR ≥25 and ≤65 mL/min/1.73 
m2, or ages 56−65 years with eGFR ≥25 and ≤44 mL/min/1.73 m2 and evidence of ADPKD 
progression (an eGFR decline of >2.0 mL/min/1.73 m2/year based on historical eGFR data). Based 
on the above enrollment criteria, TEMPO 3:4 had a trial population in CKD stages 1-3, >80% in 
stage 1 or 2 CKD. In REPRISE, 75% of subjects were in stage 3 and 20% were in stage 4 CKD. A post 
hoc analysis of the TEMPO 3:4 trial population indicated a population enriched for high risk of rapid 
progression, with 89.5% of the population in Mayo risk classes 1C-1E versus 60.5% in an 
unselected ADPKD population of Mayo Clinic patients.19 
 
Outcomes Evaluated in the Post-Hoc Analyses 
The effect of tolvaptan on rate of change in eGFR in each trial was evaluated for the 
subgroup of completers, i.e., subjects who continued to take the trial drug to the end of the 
treatment period in TEMPO 3:4 (3 years) or REPRISE (1 year). Similarly, the effect of tolvaptan on 
annualized rate of TKV growth was calculated for the completer subpopulation in TEMPO 3:4 (TKV 
was not assessed in REPRISE).  
To further explore determinants of tolvaptan treatment effects on kidney function in 
ADPKD, subgroup analyses of change in eGFR over time by baseline demographic and clinical 
variables were performed. Finally, subject characteristics by completer/non-completer status were 













Analysis of efficacy endpoints was based on the methods used in each trial and using the full 
trial datasets. For TEMPO 3:4,  comparisons between tolvaptan completers and placebo completers 
were derived by testing the time treatment interaction with a linear mixed model in which both 
intercept and slope are fixed and random effects. For REPRISE, the comparison was derived from a 
weighted analysis of covariance with effects of treatment and randomization stratification factors 
and covariate baseline. 
In an analysis of the effects of baseline variables, we compared eGFR slope between subjects 
from TEMPO 3:4 and REPRISE who were matched by propensity score for gender, age, and baseline 
eGFR. Propensity score-based matching was used to exclude the effects of differences in trial 
populations (for example, in the proportions of subjects with early versus late-stage CKD) and 
assess the treatment effects of tolvaptan in subjects with similar clinical profiles. For the propensity 
analysis, the SAS procedure PROC PSMATCH was utilized in three steps with the local optimal 
algorithm, caliper=0.03, and the sex as exact match. In Step 1, TEMPO 3:4 placebo subjects were 
matched to TEMPO 3:4 tolvaptan subjects. The total absolute difference in the logit of the 
propensity score for all matches was 0.692729. In Step 2, REPRISE tolvaptan subjects were 
matched to the TEMPO 3:4 tolvaptan subjects found in Step 1. The total absolute difference in the 
logit of the propensity score for all matches was 1.722285. In Step 3, REPRISE placebo subjects 
were matched to TEMPO 3:4 placebo subjects found in Step 1. The total absolute difference in the 
logit of the propensity score for all matches was 0.78467. 
In a comparison of subject characteristics by completer/non-completer status, P-values 
were derived by Fisher's Exact Test for binary characteristics and by T-test/Wilcoxon Test for 
continuous characteristics.                                                               
 
RESULTS 











In TEMPO 3:4, 740/961 (77.0%) subjects randomized to the tolvaptan arm and 417/484 
(86.2%) randomized to the placebo arm completed the trial on treatment.12 In REPRISE, the 
number of completers was 578/683 (84.6%) for tolvaptan and 637/687 (92.7%) for placebo.13 
Several completers in each trial had missing or unusable eGFR data, yielding an efficacy analysis 
population of 713 tolvaptan and 410 placebo completers for TEMPO 3:4 and 576 tolvaptan and 634 
placebo completers for REPRISE (Figure 1). Testing of the potential interaction between completer 
status and treatment found no treatment difference between completers and non-completers in 
either TEMPO 3:4 (P=0.4846) or REPRISE (P=0.0924). 
 
Efficacy in the Completer Subpopulation 
In both TEMPO 3:4 and REPRISE, rates of change in eGFR with tolvaptan and placebo were 
very similar between the total trial population and the subgroup of treatment completers (Figure 
2). Accordingly, the treatment effect of tolvaptan versus placebo was also similar between the total 
population and the subgroup of treatment completers. Annualized TKV growth rate was 2.8% for 
subjects in the tolvaptan group and 5.5% for those in the placebo group in the total TEMPO 3:4 
population (P<0.001).12 Among the subgroup of TEMPO 3:4 completers, annualized TKV growth 
rate was 2.7% for subjects in the tolvaptan group and 5.5% for those in the placebo group 
(P<0.001). As with rates of change in kidney function, rates of TKV growth in the subpopulation of 
completers were similar to those in the total trial population. 
 
Impact of Baseline Characteristics 
Subgroup analyses of completers by baseline characteristics showed that tolvaptan was 
efficacious versus placebo in slowing renal function decline regardless of age, sex, or race in both 











and placebo were in subgroups with low subject numbers: non-Caucasian subjects in TEMPO 3:4 
and REPRISE and subjects aged >55 years in REPRISE.  
Propensity score matching for gender, age, and baseline eGFR generated an analysis set of 
108 subjects for each trial (54 subjects in each of the tolvaptan and placebo treatment arms). 
Gender composition was 23 females (43%) and 31 males (57%) in each matched tolvaptan and 
placebo group, and mean age was 42–44 years (Figure 3A). The mean eGFR (~53 mL/min/1.73 m2) 
in the matched population fell within CKD stage 3a, indicating the area of overlap in the two trial 
populations between subjects with early to moderate stage CKD (TEMPO 3:4) and subjects with 
moderate to late stage CKD (REPRISE) (Figure 3B). The baseline characteristics of the matched 
population are provided in Supplementary Table S3 and the age and CKD stage distributions are 
shown in Supplementary Figure S1. In the matched population, the treatment effect of tolvaptan in 
TEMPO 3:4 (1.44 mL/min/1.73 m2/year) was similar to that in REPRISE (1.89 mL/min/1.73 
m2/year), with a nonsignificant difference of -0.45 (P = 0.71) (Figure 4). 
Analyses of baseline demographic and clinical characteristics revealed potential 
associations of age, body mass index, use of blood pressure lowering drugs, history of hematuria, 
and history of kidney pain with treatment completion in TEMPO 3:4 but not REPRISE (Table).  
 
DISCUSSION 
Tolvaptan has demonstrated statistically and clinically significant efficacy in reducing the 
rate of kidney function decline in ADPKD patients with both early-stage and later-stage CKD, with 
slight differences observed in the tolvaptan effect sizes between the total TEMPO 3:4 and REPRISE 
populations. In TEMPO 3:4, the annualized mean change in eGFR was reduced by 1.20 
mL/min/1.73 m2/year with tolvaptan vs. placebo.13  In REPRISE, tolvaptan reduced the annualized 
mean change in eGFR by 1.27 mL/min/1.73 m2/year.13 In TEMPO 3:4, the annualized eGFR slope 










placebo group (a difference of 0.98 mL/min/1.73 m2/year; 95% CI, 0.60 to 1.36; P<0.001).12 In 
REPRISE, annualized eGFR slope was −3.16 mL/min/1.73 m2/year with tolvaptan and −4.17 
mL/min/1.73 m2/year with placebo, a significant difference of 1.01 mL/min/1.73 m2/year (95% CI, 
0.62 to 1.40; P<0.001).13  
The slightly greater tolvaptan treatment effects in REPRISE might plausibly be ascribed to 
the higher frequency of tolvaptan discontinuation during double-blind treatment in TEMPO 3:4 
(23.0%) compared to REPRISE (15.0%). In this post hoc analysis, we evaluated the hypothesis that 
subjects completed their respective trials on treatment would show a larger effect size than those 
who discontinued treatment early. No difference in effect size, however, was found between the 
total trial population and the subgroup of completers. Tolvaptan was generally effective versus 
placebo in subgroups of completers defined by baseline age, sex, and race. The treatment difference 
between tolvaptan and placebo was not significant in non-Caucasian subjects in both trials and in 
subjects aged >55 years in REPRISE, observations that may have been due to the small sample sizes 
of these subgroups. Given the lack of impact of treatment completion and demographic 
characteristics on outcomes, the small differences in tolvaptan treatment effect between TEMPO 
3:4 and REPRISE therefore appear to be due to differences in disease stage between the trial 
populations, namely, earlier-stage CKD in TEMPO 3:4 and later-stage CKD in REPRISE. 
Deterioration in kidney function accelerates over the course of ADPKD, enabling the easier 
detection of inhibitory effects on eGFR decline in patients with later-stage disease.20,21  
The importance of CKD stage at baseline is supported by the observation that when 
differences in subject baseline characteristics were accounted for via propensity matching, the 
treatment effect was not significantly different between TEMPO 3:4 and REPRISE. The lack of a 
significant treatment difference observed between tolvaptan and placebo within the matched 
REPRISE population may be due to the small size of the propensity matched subgroup relative to 










TKV in TEMPO 3:4 completers versus the total trial population showed similar results to the eGFR 
analyses, with little evident effect of completion on outcomes. 
Tolvaptan was consistently associated with a slowing of eGFR decline by approximately 1 
mL/min/1.73 m2/year relative to placebo in TEMPO 3:4 and REPRISE across completers and the 
overall trial populations. Although evaluating the efficacy of treatment for ADPKD remains an 
under-researched topic and there are no generally agreed on standards for the clinic,22 a slowing of 
eGFR loss of 1 mL/min/1.73 m2/year is clinically meaningful and can be expected to substantially 
slow progression to ESKD.23 Similarly, tolvaptan slowed the annual increase in TKV by 
approximately half, which can be expected to make an impact on patient outcomes and quality of 
life over the long-term. 
We found associations between baseline characteristics and treatment completion in 
TEMPO 3:4. Subjects who were older or took blood pressure medication were more likely to be 
completers, possibly because they were already accustomed to daily pharmacotherapy. Mean 
baseline blood pressure itself did not significantly differ by completer/non-completer status. A 
history of hematuria or kidney pain was negatively associated with treatment completion. Previous 
research on predictors of medication utilization supports a positive association between older age 
and better adherence, whereas data on the impact of comorbidity or the use of multiple 
medications on adherence are equivocal.24–26 Lower body mass index was also positively associated 
with treatment completion in TEMPO 3:4. The finding of correlations between subject 
characteristics and completer/non-completer status in TEMPO 3:4 but not REPRISE may be due to 
the longer treatment period in TEMPO 3:4 (three years vs. one year). Differences in trial design and 
trial populations between TEMPO 3:4 and REPRISE must also be borne in mind. The double-blind 
treatment phase of REPRISE included only subjects who tolerated tolvaptan during a preceding 
single-blind phase. Subjects enrolled in REPRISE may also have been aware of the earlier TEMPO 











tolerate aquaretic adverse events. Given the established association of decreased drug compliance 
with negative health outcomes in chronic conditions, more research on predictors of medication 
persistence is needed in the context of treatment for ADPKD.27,28   
Limitations of the analysis are the post hoc nature of the analyses and the relatively small 
proportion of non-completers in each trial arm (ranging from 7.7% to 23.0%). The small number of 
non-completers may have decreased the power to detect differential effects of completer versus 
non-completer status. When REPRISE was conducted, more was understood about the short-term 
hemodynamic effects of tolvaptan, with the timing of eGFR assessments designed to take these 
effects into account in evaluating long-term efficacy. The assessment of treatment effect was 
therefore not identical between TEMPO 3:4 and REPRISE. Additionally, outcomes after drug 
discontinuation were monitored differently in each trial. In REPRISE, eGFR data after 
discontinuation were included in the dataset for the overall population only for subjects who 
underwent the Month 12 visit and at least 1 follow-up serum creatinine assessment. In TEMPO 3:4, 
there was no requirement for follow-up after discontinuation to extend to end of study. 
Accordingly, the TEMPO 3:4 data may provide a less robust pool of data on non-completers. 
Within the context of the demonstrated efficacy of tolvaptan in ADPKD subjects with early- 
to late-stage CKD, the most important factor in determining tolvaptan effect size in inhibiting eGFR 
decline appears to be stage of kidney disease at treatment commencement. This conclusion is 
consistent with earlier findings.20 Given that kidney function decline accelerates with the 
progression of ADPKD, the effects of tolvaptan in slowing kidney function loss are most easily 
discernible in later-stage patients. In clinical practice, monitoring kidney function to assess the 
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Table. Baseline characteristics of TEMPO 3:4 and REPRISE participants by completer status 
 











Male, n (%) 605 (52) 141 (49) 0.32 612 (50) 68 (44) 0.15 
Age (yr), mean (SD)  39.03 (6.97) 37.15 (7.47) <.001 47.38 (8.05) 46.33 (8.99) 0.13 
Age ≤55 yr, n (%) 1157 (100) 288 (100)  1041 (86) 132 (85) 0.90 
Caucasian, n (%)            972 (84) 246 (85) 0.59 1117 (92) 141 (91) 0.64 
BMI (kg/m2), mean (SD)                  25.95 (4.79) 26.88 (5.93) 0.005 27.87 (5.71) 27.71 (5.77) 0.75 
SBP (mmHg), mean (SD)                   128.4 (13.59) 129.0 (13.21) 0.51 129.5 (14.09) 131.1 (14.23) 0.19 
DBP (mmHg), mean (SD) 82.44 (9.63) 82.59 (10.08) 0.81 82.18 (9.62) 83.52 (10.17) 0.10 
BPLD use, n (%)              856 (74) 191 (66) 0.01 1060 (87) 129 (83) 0.17 
RAASi use, n (%)               848 (73) 191 (66) 0.02 1049 (86) 127 (82) 0.14 
Cholesterol (mmol/L), mean (SD)     5.00 (0.91) 5.03 (0.97) 0.71 5.04 (1.01) 4.99 (0.95) 0.55 
Hypercholesterolemia, n (%)    287 (25) 68 (24) 0.70 546 (45) 60 (39) 0.15 
LLD use, n (%)              149 (13) 30 (10) 0.27 396 (33) 45 (29) 0.41 
Glucose (mmol/L), mean (SD)          5.19 (0.80) 5.22 (0.90) 0.63 5.15 (0.83) 5.04 (0.69) 0.13 
Diabetes mellitus, n (%) 1 (0) 0 (0) 1.00 28 (2) 4 (3) 0.78 
GLD use, n (%)              0 (0) 0 (0)  28 (2) 4 (3) 0.78 
Hematuria, n (%) 388 (34) 115 (40) 0.05 333 (27) 44 (28) 0.78 
Kidney pain, n (%) 567 (49) 168 (58) 0.005 607 (50) 75 (48) 0.73 
Kidney stone, n (%) 225 (19) 71 (25) 0.06 247 (20) 33 (21) 0.75 
Upper UTI (kidney/bladder), n (%) 355 (31) 99 (34) 0.23 292 (24) 38 (25) 0.92 
eGFR (CKD-EPI), mean (SD)             81.13 (21.47) 83.53 (22.05) 0.09 41.13 (10.99) 39.92 (11.52) 0.25 











Total kidney volume ≤2000 mL, n (%)a    131 (11) 18 (12) 0.78 
Urine osmolality (mOsm/kg), mean (SD)b  498.4 (180.0) 515.3 (173.4) 0.15 168.8 (61.12) 169.1 (66.36) 0.95 
P-values were derived by Fisher's Exact test for binary characteristics. P-values were derived by T-test/Wilcoxon test for continuous characteristics.                                                               
aTotal kidney volume was not assessed in REPRISE. During the screening period for REPRISE, the subject’s eligibility for the trial was confirmed using historical imaging data and recorded 
total kidney volume, if available. Randomization was stratified in REPRISE by total kidney volume ≤2000 mL, >2000 mL, or unknown. Baseline total kidney volume was unknown for 80% of 
subjects.  
bUrine osmolality in TEMPO3:4 was collected on the day of randomization prior to participant exposure to tolvaptan. Urine osmolality in REPRISE was also collected on the day of 
randomization however this was at the completion of active tolvaptan run-in and therefore whilst participants were exposed to fully titrated tolvaptan. 
BMI, body mass index; BPLD, blood pressure-lowering drugs; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; DBP, diastolic blood pressure; eGFR, estimated glomerular 
filtration rate; GLD, glucose-lowering drugs; IQR, interquartile range; LLD, lipid-lowering drugs; RAASi, renin-angiotensin-aldosterone system inhibitors; SBP, systolic blood pressure; SD, 















Figure 1. Subject flow 
 
Figure 2. Effect of tolvaptan on eGFR change (mL/min/1.73 m2/year) in the total trial population and treatment completer 
subset of TEMPO 3:4 (A) and REPRISE (B). aComparison of tolvaptan vs placebo within each analysis population. Data are ± 95% 
confidence interval for TEMPO 3:4 and ± standard error for REPRISE. eGFR, estimated glomerular filtration rate; PBO, placebo; TOL, 
tolvaptan. 
 
Figure 3. (A) Eligible ages for trial enrollment and mean age of subjects matched by propensity score. (B) Eligible eGFR for trial 
enrollment and mean eGFR of subjects matched by propensity score. eGFR, estimated glomerular filtration rate; PBO, placebo; TOL, 
tolvaptan. 
 
Figure 4. Tolvaptan effect on eGFR slope (mL/min/1.73 m2/year) in TEMPO 3:4 and REPRISE in subjects matched by propensity 
score (A). Comparison of tolvaptan effect on eGFR slope (mL/min/1.73 m2/year) between TEMPO 3:4 and REPRISE in subjects 
matched by propensity score (B). aComparison of TOL vs PBO in the subset of propensity-matched subjects within TEMPO 3:4 and 
REPRISE. bComparison of TOL effect between TEMPO 3:4 and REPRISE. eGFR data are ± standard error. eGFR, estimated glomerular 
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Conclusion Treatment completion had little impact on eGFR outcome. More rapid 
decline in kidney function in later-stage CKD enabled the effects of tolvaptan to be 
more easily discerned. Similar results between trials in subjects matched for 
























54 matched subjects in each 
treatment group in each study
Treatment effect on eGFR* (difference vs placebo)
TEMPO 3:4 
REPRISE






Statistically similar treatment effect of 
Tolvaptan in matched subjects
TEMPO 3:4 vs REPRISE -0.446 0.7068
P-valueDifference*
*mL/min/1.73m2/year
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